companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories














  • Regeneron | Pushing the Bounds of Science
    Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines Join our team and explore clinical trials
  • About Regeneron | Our Company
    Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases
  • Investor Relations | Regeneron Pharmaceuticals Inc.
    The Investor Relations website contains information about Regeneron Pharmaceuticals Inc 's business for stockholders, potential investors, and financial analysts
  • Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to . . .
    TARRYTOWN, N Y , June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) today announced interim results from the ongoing Phase 2 COURAGE trial investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8 anti-myostatin) with or without garetosmab (anti-activin A) for the treatment of obesity The trial demonstrated that
  • PUSH THE BOUNDS OF SCIENCE - Regeneron
    Regeneron is a leading biotechnology company dedicated to inventing, developing and commercializing life-transforming medicines for people with serious diseases
  • Regeneron snags FDA nod for myeloma bispecific Lynozyfic
    Another BCMA-targeted agent has arrived for the treatment of multiple myeloma | After a delay, Regeneron’s BCMA-directed bispecific antibody Lynozyfic has won an FDA approval with a more
  • US FDA approves Regenerons blood cancer therapy - MSN
    By Puyaan Singh (Reuters) -Regeneron Pharmaceuticals said on Wednesday the U S Food and Drug Administration has approved its drug for a type of blood cancer called multiple myeloma that has
  • Jobs - Regeneron Careers
    You choose Regeneron Submit an application to the role that best suits your skill set and career goals




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer